- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02532049
A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313
A Phase Ia Clinical Trial to Assess the Safety, Immunogenicity and Ex-vivo Efficacy of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 Pfs-IMX313 Alone and With MVA Pfs25-IMX313
This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. ChAd Pfs-IMX313 will either be administered alone or with MVA Pfs25-IMX313 in a prime-boost regime.
All vaccines will be administered intramuscularly.
Group 1 will receive one dose of ChAd63 Pfs25-IMX313 at 5x10^9 vp.
Group 2A will receive one dose of ChAd63 Pfs-IMX313 at 5x10^10 vp.
Group 2B will receive one dose of ChAd63 Pfs-IMX313 at 5x10^10 vp and one dose of MVA Pfs25-IMX313 at 1x10^8 pfu eight weeks later.
Group 2C will receive one dose of ChAd63 Pfs25-IMX313 at 5x10^10 vp and one dose of MVA Pfs25-IMX313 at 2x10^8 pfu eight weeks later.
The study will assess the safety of the vaccinations, and the immune responses to the vaccination. Immune responses are measured by tests on blood samples.
Healthy volunteers will be recruited in Oxford and Southampton, England.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Oxford, Det Forenede Kongerige, OX3 7LE
- CCVTM, University of Oxford, Churchill Hospital
-
Southampton, Det Forenede Kongerige, SO16 6YD
- NIHR Wellcome Trust Clinical Research Facility
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
The volunteer must satisfy all the following criteria to be eligible for the study:
- Healthy adults aged 18 to 50 years
- Able and willing (in the Investigator's opinion) to comply with all study requirements
- Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
- For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination
- Agreement to refrain from blood donation during the course of the study
- Provide written informed consent
Exclusion Criteria:
The volunteer may not enter the study if any of the following apply:
- Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
- Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data.
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products.
- Any history of anaphylaxis in relation to vaccination
- Pregnancy, lactation or willingness/intention to become pregnant during the study
- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- History of serious psychiatric condition likely to affect participation in the study
- Any other serious chronic illness requiring hospital specialist supervision
- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
- Suspected or known injecting drug abuse in the 5 years preceding enrolment
- Seropositive for hepatitis B surface antigen (HBsAg)
- Seropositive for hepatitis C virus (antibodies to HCV)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Group 1
ChAd63 Pfs25-IMX313 (5x10^9 vp)
|
|
Aktiv komparator: Group 2A
ChAd63 Pfs25-IMX313 (5x10^10 vp)
|
|
Aktiv komparator: Group 2B
ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (1x10^8 pfu) 8 weeks later
|
|
Aktiv komparator: Group 2C
ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (2x10^8 pfu) 8 weeks later
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Adverse Events
Tidsramme: 8 months
|
The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.
|
8 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Immunogenicity of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime.
Tidsramme: 8 months
|
8 months
|
Ex-vivo efficacy of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime. The functional activity of the vaccine induced antibodies will be tested using membrane-feeding assays.
Tidsramme: 8 months
|
8 months
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- VAC062
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts... og andre samarbejdspartnereRekrutteringPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLaos Demokratiske Folkerepublik
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanAfsluttetVivax malaria | Ukompliceret Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaAfsluttetPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis... og andre samarbejdspartnereAfsluttetMalaria | Vivax malaria | Falciparum malariaEtiopien, Bangladesh, Indonesien
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AfsluttetVivax malaria | Falciparum malariaIndonesien
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology og andre samarbejdspartnereAfsluttet
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet TPO og andre samarbejdspartnereAfsluttetMalaria | Vivax malaria | Falciparum malariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AfsluttetVivax malaria | Falciparum malariaIndonesien
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationAfsluttetMalaria | Vivax malaria | Falciparum malaria | Malaria Genopblomstring
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute for Advanced Medical Research and Training, University of Ibadan, IbadanAfsluttetPlasmodium Falciparum Malaria | Ukompliceret malaria | Malaria feberNigeria
Kliniske forsøg med ChAd63 Pfs25-IMX313
-
University of OxfordIfakara Health InstituteRekruttering
-
University of OxfordAfsluttetMalaria, FalciparumDet Forenede Kongerige
-
Eunice Kennedy Shriver National Institute of Child...Trukket tilbageMalaria | Plasmodium Falciparum Malaria | Malariavacciner
-
University of OxfordAktiv, ikke rekrutterendeMalaria, VivaxDet Forenede Kongerige
-
University of OxfordImaxioAfsluttetTuberkulose (TB)Det Forenede Kongerige
-
University of YorkWellcome Trust; European and Developing Countries Clinical Trials Partnership... og andre samarbejdspartnereTrukket tilbage
-
U.S. Army Medical Research and Development CommandUnited States Agency for International Development (USAID); University... og andre samarbejdspartnereAfsluttet
-
Fraunhofer, Center for Molecular BiotechnologyAfsluttet
-
University of YorkUniversity of KhartoumAfsluttet
-
University of YorkAfsluttet